¥ 139
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
PRISM BioLab Co., LTD. engages in the research and development of pharmaceuticals using its proprietary drug discovery platform, PepMetics Technology. The company's technology focuses on creating peptide mimetic small molecules designed to mimic α-helix or β-turn peptides, which are essential for protein-protein interactions. Through its platform, PRISM aims to discover drugs for what were previously considered 'undruggable targets,' with a pipeline including candidates for cancer and fibrotic diseases.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only